Author:
Raemaekers John M. M.,Engert Andreas
Publisher
Springer Berlin Heidelberg
Reference30 articles.
1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6.
2. Specht L, Raemaekers J. Do we need an early unfavorable (intermediate) stage of Hodgkin’s lymphoma? Hematol Oncol Clin North Am. 2007;21:881–96.
3. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24:3128–35.
4. Hoerni B, Orgerie MB, Eghbali H, et al. New combination of epirubicine, bleomycin, vinblastine and prednisone (EBVP II) before radiotherapy in localized stages of Hodgkin’s disease. Phase II trial in 50 patients. Bull Cancer. 1988;75:789–94.
5. Pavlovsky S, Schvartzman E, Lastiri F, et al. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin’s disease. J Clin Oncol. 1997;15:2652–8.